Anti-VEGF Injections for Wet AMD: Ranibizumab vs. Aflibercept vs. Bevacizumab

Research-informed explainer — last updated April 12, 2026

Anti-VEGF injections have transformed wet macular degeneration from a condition that almost always caused severe vision loss into one that, with consistent treatment, most patients can manage while preserving useful sight. The three drugs most commonly used — ranibizumab, aflibercept, and bevacizumab — are closely matched in efficacy but differ substantially in cost, dosing schedules, and FDA approval status, making the choice a meaningful conversation between patient and physician.

This article draws on research from five specialist physicians whose work spans the pivotal trials that defined this treatment era. Jeffrey Heier, MD, Co-President and Medical Director at Ophthalmic Consultants of Boston, was an investigator on the MARINA ranibizumab trial (5,820 citations), the ANCHOR ranibizumab vs. verteporfin trial (3,477 citations), and the VIEW aflibercept trial (2,433 citations) — a rare vantage point covering two of the three main drugs. Evangelos Gragoudas, MD, at Massachusetts General Hospital, led the VISION pegaptanib trial (2,309 citations), the first-ever anti-VEGF therapy for AMD, providing the historical foundation of this entire treatment class. Srinivas Sadda, MD, A. Ray Irvine Jr. Endowed Chair at UCLA and the Doheny Eye Institute, published the AMD clinical classification system (1,763 citations) and seven-year outcomes across the ANCHOR, MARINA, and HORIZON trials (999 citations). Susan Bressler, M.D., at Johns Hopkins Bayview Medical Center, contributed landmark data on ranibizumab for diabetic macular edema (1,425 citations). Tien Wong, M.D., at Houston Methodist Hospital, authored the global AMD prevalence meta-analysis projecting 288 million people affected by 2040 (5,098 citations).

What is wet AMD and why does VEGF matter?

Age-related macular degeneration affects the macula — the central portion of the retina responsible for sharp, detailed vision. In the "wet" form, abnormal blood vessels grow beneath the retina and leak fluid, distorting and destroying central vision rapidly. These abnormal vessels grow in response to a protein called vascular endothelial growth factor (VEGF). Blocking VEGF with injections into the eye stops vessel growth and, in many patients, allows fluid to reabsorb and vision to improve or stabilize.

Before anti-VEGF therapy existed, wet AMD caused severe vision loss in most patients within two years of diagnosis. The introduction of pegaptanib (the first anti-VEGF) in 2004 — established through Dr. Gragoudas's VISION trial — was the proof-of-concept. More potent pan-VEGF blockers that followed changed the prognosis dramatically.

According to Tien Wong's meta-analysis, approximately 196 million people worldwide had AMD in 2020, with that number projected to rise to 288 million by 2040 — making it one of the most prevalent causes of legal blindness in high-income countries.

The three main drugs: how they work

All three FDA-approved agents (and bevacizumab, which is used off-label) block VEGF from binding to its receptors on blood vessel walls, preventing new vessel growth and reducing leakage.

• Ranibizumab (Lucentis): A monoclonal antibody fragment designed specifically for the eye. FDA-approved in 2006 for wet AMD.
• Aflibercept (Eylea): A fusion protein that acts as a "VEGF trap," binding VEGF with higher affinity than ranibizumab and also blocking placental growth factor (PlGF). FDA-approved for wet AMD in 2011.
• Bevacizumab (Avastin): A full-length antibody developed as a cancer drug but widely used off-label for wet AMD at roughly 1/40th the cost of ranibizumab. Not FDA-approved for ocular use.

Comparison table

What the trials showed

MARINA (2006): Dr. Heier and colleagues enrolled 716 patients with minimally classic or occult wet AMD. At two years, 94.5% of patients treated with monthly ranibizumab lost fewer than 15 letters of visual acuity, compared with 62% of untreated controls. About one-third of treated patients gained 15 or more letters — a meaningful functional improvement.

ANCHOR (2006): In 423 patients with predominantly classic neovascularization, ranibizumab outperformed photodynamic therapy with verteporfin at every time point. At one year, 40% of ranibizumab patients gained 15 or more letters versus 6% with verteporfin.

VIEW 1 and 2 (2012): Dr. Heier also participated in these trials comparing aflibercept to ranibizumab across 2,457 patients. Aflibercept given every two months (after three monthly loading doses) produced outcomes statistically equivalent to monthly ranibizumab — a clinically important finding because less frequent injections matter enormously to patients with transportation challenges or needle anxiety.

Long-term durability: Dr. Sadda's analysis of 7-year outcomes across the ANCHOR, MARINA, and HORIZON extension trials found that visual acuity gains were largely maintained in patients who continued treatment, but approximately 50% of patients had lost at least 15 letters from their best-ever on-treatment acuity by year 7 — underscoring that consistent, ongoing treatment is not optional.

CATT (Comparison of AMD Treatments Trial): This NIH-funded head-to-head enrolled 1,185 patients and found that bevacizumab was non-inferior to ranibizumab when given monthly, with nearly identical mean visual acuity gains at one and two years. Dr. Bressler contributed to this trial's analysis. The result validated off-label bevacizumab use and established the cost argument squarely.

How your doctor chooses

In clinical practice, the choice among these agents is influenced by several factors:

Insurance and cost: For commercially insured or Medicare patients, ranibizumab and aflibercept are reimbursed under Medicare Part B (buy-and-bill). Bevacizumab requires compounding and is not FDA-approved for ocular use, which creates regulatory complexity but offers savings that matter for patients with high copays.

Dosing schedule preference: Aflibercept's approved every-two-month maintenance dosing (after the loading phase) can reduce the burden of monthly visits. High-dose aflibercept 8 mg (Eylea HD), approved in 2023, extends the interval to every three to four months for some patients.

Disease activity: Patients with very active disease — ongoing fluid, new hemorrhage — may do better with monthly dosing regardless of which drug is chosen.

Physician familiarity: Many retina specialists switch between agents when a patient's OCT shows persistent subretinal fluid after several injections of one drug. This "switching" strategy is commonly used in practice, though head-to-head switching data are limited.

What to expect from injections

Each injection takes only a few minutes. The eye is numbed with drops or a small subconjunctival injection of anesthetic. The drug is delivered through the white part of the eye (sclera) with a very fine needle, typically below and to the side. Most patients describe pressure or mild discomfort rather than pain. Vision may be slightly blurry for an hour or two afterward.

Serious adverse events — including endophthalmitis (eye infection) and retinal detachment — occur in less than 0.1% of injections in clinical trials. Systemic risks (stroke, heart attack) from absorbed VEGF inhibition are theoretically possible but have not been demonstrated to differ meaningfully among the three drugs in large trials.

Questions to ask your doctor

• Which drug do you recommend for my type of wet AMD, and why?
• How often will I need injections in the first year, and what is the maintenance schedule likely to look like?
• What signs on my OCT images tell you whether the drug is working?
• Is bevacizumab an appropriate option for me, and what are the cost implications of each choice?
• What happens if I cannot make every scheduled appointment?
• At what point would you consider switching me to a different agent?

The bottom line

Ranibizumab, aflibercept, and bevacizumab all prevent vision loss and often improve vision in wet AMD — and clinical trial data support each as a reasonable first choice. The practical differences come down to approved dosing intervals (aflibercept allows every-two-month maintenance), cost (bevacizumab is dramatically cheaper), and individual disease activity. Long-term data from Dr. Sadda's cohort analysis make clear that sustained treatment over years, not months, is what preserves vision — making adherence and access to care as important as which drug is chosen.